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Tetramethylpyrazine nitrone, a 
multifunctional neuroprotective 
agent for ischemic stroke therapy
Zaijun Zhang1,*, Gaoxiao Zhang1,*, Yewei Sun1,*, Samuel S. W. Szeto2, Henry C. H. Law2, 
Quan Quan2, Guohui Li2, Pei Yu1, Eiketsu Sho3, Michael K. W. Siu4, Simon M. Y. Lee5, 
Ivan K. Chu2 & Yuqiang Wang1
TBN, a novel tetramethylpyrazine derivative armed with a powerful free radical-scavenging nitrone 
moiety, has been reported to reduce cerebral infarction in rats through multi-functional mechanisms 
of action. Here we study the therapeutic effects of TBN on non-human primate model of stroke. Thirty 
male Cynomolgus macaques were subjected to stroke with 4 hours ischemia and then reperfusion. 
TBN were injected intravenously at 3 or 6 hours after the onset of ischemia. Cerebral infarction was 
examined by magnetic resonance imaging at 1 and 4 weeks post ischemia. Neurological severity scores 
were evaluated during 4 weeks observation. At the end of experiment, protein markers associated 
with the stroke injury and TBN treatment were screened by quantitative proteomics. We found that 
TBN readily penetrated the blood brain barrier and reached effective therapeutic concentration after 
intravenous administration. It significantly reduced brain infarction and modestly preserved the 
neurological function of stroke-affected arm. TBN suppressed over-expression of neuroinflammatory 
marker vimentin and decreased the numbers of GFAP-positive cells, while reversed down-regulation 
of myelination-associated protein 2′, 3′-cyclic-nucleotide 3′-phosphodiesterase and increased the 
numbers of NeuN-positive cells in the ipsilateral peri-infarct area. TBN may serve as a promising new 
clinical candidate for the treatment of ischemic stroke.
Stroke is one of the most devastating diseases affecting the health and life of human beings. Despite the remark-
able progresses achieved in the last two decades in understanding the pathophysiology of stroke, tissue-type 
plasminogen activator (tPA) remains the sole therapeutics approved by the US FDA for the treatment of acute 
ischemic stroke. However, tPA has a narrow therapeutic window of 3–4.5 h within the occurrence of a stroke, lim-
iting its clinical use. Besides, tPA has no neuroprotective effect. Although many pharmacological agents for stroke 
have shown considerable promise in rodent models, none have successfully been translated for use in humans1. 
Nevertheless, finding an effective neuroprotective agent remains a strongly sought after goal2,3.
One of the most extensively studied classes of neuroprotective agents is free radical scavengers, as free radical 
over-production is a major contributor to brain injury after stroke. NXY-059, a free radical-trapping nitrone, 
showed positive results when evaluated in various animal stroke models but failed its second phase III clinical trial4,5. 
The cause of this failure is multifactorial, including poorly designed preclinical and clinical studies6 and its poor 
ability in penetrating the blood-brain barrier (BBB)7,8. Edaravone, also a free radical scavenger, has been approved 
for treatment of patients with ischemic stroke in Japan9 and China. However, it is not approved for use in Western 
countries due to limited efficacy and side effects, such as acute renal failure, liver dysfunction and acute allergic 
reactions10.
Tetramethylpyrazine (TMP), a main active ingredient of Ligusticum wallichii Franchat (Chuanxiong), has been 
widely used as a treatment of ischemic stroke for a long time in China11. However, until now, there has not ever 
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been a methodologically sound clinical trial demonstrating its benefit. Although the exact mechanisms of action 
of TMP have not been completely understood, a variety of mechanisms may be attributed to its beneficial effects 
in stroke patients, including inhibiting platelet aggregation, lysing blood clots, blocking intracellular calcium 
entry and scavenging free radicals12. Nitrone is originally developed as free radical-trapping agents in free radical 
chemistry, potently scavenges free radicals and protects biological systems from oxidative stress8. Nitrones have 
been tested as therapeutic agents for neural and systemic dysfunctions including atherosclerosis, septicemia, 
stroke, and Alzheimer’s disease13,14. Taking advantage of the beneficial effects of both TMP and nitrone, there-
fore, we designed and synthesized (2-[[(1,1-dimethylethyl)oxidoimino]-methyl]-3,5,6-trimethylpyrazine, TBN), 
a TMP derivative armed with a powerful free radical-scavenging nitrone moiety. TBN was desired to possess the 
pharmacological properties of both TMP and nitrone.
We previously demonstrated that TBN protected rats from ischemic stroke damage15,16. A multi-functional 
mechanisms possibly contributed to TBN’s beneficial effects in stroke models, including directly scavenging var-
ious free radicals, blockade of calcium entry and inhibition of platelet aggregation16. To bridge the biological gap 
between the rodent animal experiments and clinical trials, in the present study, we investigated the therapeutic 
efficacy of TBN in non-human primate (NHP) model of ischemic stroke, as well as its pharmacokinetics, fulfilling 
the requirements for initiating investigational new drug application.
Results
TBN reduces cerebral infarction and improves neurological functions in stroke monkeys. We 
evaluated TBN in M. fascicularis (cynomolgus macaque) subjected to t-MCAo. At one week post-surgery, TBN 
treatment administered at 3 h post-ischemia caused a reduction in overall infarct size in a dose-dependent man-
ner as measured by T2-weighted MRI scans (Fig. 1A,B). Since only a small percentage (~3%) of stroke patients 
receive therapeutic intervention within 3 h after onset of ischemic stroke17, it was important to establish whether 
TBN is effective even under delayed treatment scenarios. TBN was found to be effective even when administered 
6 h post-ischemia, indicating the potential for an expanded therapeutic window (Fig. 1A,B). At four weeks, sim-
ilar dose-dependent trends were observed, with all treatments resulting in significant reductions in infarct size 
(Fig. 1A,C).
Functional neurological assessments were performed throughout the 28-day observation period, which ascer-
tained that TBN treatment ameliorated the long-term neurological impairment produced by t-MCAo. Monkeys 
treated with TBN trended to have lower neurological deficit scores at 1 and 4 weeks post-ischemia (Table 1). 
Scores included assessments of consciousness, sensory and motor system function, and skeletal muscle coordi-
nation. Impressively, at 4 weeks post-ischemia, both the 30 and 90 mg kg−1 TBN treatment regiments produced a 
~50% recovery of arm function, as demonstrated by the restored ability of the contralateral, stroke-affected arm 
to acquire food (Fig. 1D and see Supplementary Movie 1and 2).
TBN readily penetrates the blood-brain barrier and reaches therapeutic concentration. One 
reason that NXY-059 failed in clinical trials was its poor penetration of the BBB, with only 1% penetration in 
rats8. To investigate its ability to penetrate the BBB, TBN’s concentration in the monkey plasma and cerebrospinal 
fluid were examined. After intravenous (i.v.) administration of 30 and 90 mg kg−1 in monkeys, the plasma Cmax 
of TBN reached 370 and 549 μ M, respectively (Fig. 2A). In the CSF, the concentrations for the 30 and 90 mg kg−1 
TBN treatment regiments were 176 μ M at 15 min and 379 μ M at 45 min, respectively (Fig. 2B). At 2 h after admin-
istration, TBN was still present at concentrations of 58 and 148 μ M, respectively. TBN concentrations achieved 
in vivo were at similar levels to those (30–300 μ M) that protected cortical neurons against glutamate-induced 
excitotoxicity effectively (Fig. 2C), and attenuated oxygen and glucose deprivation (OGD)-induced release of 
lactate dehydrogenase (LDH) in cortical neurons (Fig. 2D).
Characterization of molecular events involved in neuroprotection by iTRAQ-based quantitative 
proteomic analyses. To gain insight into the molecular mechanisms underlying TBN’s neuroprotection 
in vivo, the cerebral tissues of the untreated and 30 mg kg−1 TBN-treated monkeys were subjected to iTRAQ-based 
quantitative proteomic analyses (see Supplementary Fig. S1). A total of 2935 non-redundant proteins were con-
fidently identified (local FDR < 5%) (see Supplementary Dataset 1), with the differential expression profiles 
of 1497 quantified proteins compared in the model peri-infarct tissue versus the contralateral normal tissue 
and the TBN-treated peri-infarct tissue versus the contralateral normal tissue (see Supplementary Dataset 2). 
Seven and 37 proteins were observed to be dysregulated exclusively in the untreated and TBN-treated cerebral tis-
sues, respectively, with 2 proteins showing reciprocal expression and 5 proteins being upregulated in both sample 
groups (see Supplementary Table 1 and Supplementary Dataset 3). Thirty-three of these 51 dysregulated proteins 
were functionally annotated to cellular processes associated with the chronic phase of stroke, including angiogen-
esis, neurogenesis, astrocytosis and inflammation18–22 (Fig. 3). These results revealed the major cellular processes 
associated with the observed proteomic changes. Interestingly, 8 of the 18 dysregulated proteins that were not 
annotated to the aforementioned processes are associated with various aspects of cellular energy metabolism and 
mitochondria. All were downregulated after TBN treatment (see Supplementary Table 2).
Two of the significantly dysregulated proteins, namely vimentin and 2′ ,3′ -cyclic-nucleotide 3′ -phosphodiesterase 
(CNP) were chosen for further validation using Western blotting, as changes of both vimentin and CNP have been 
previously reported in rodent models of ischemic stroke23–25. Vimentin expression was markedly up-regulated 
in the ipsilateral (Ipsi) region of the brain compared to that of the contralateral part. TBN treatment notably 
suppressed the up-regulation of vimentin in the ipsilateral region (Fig. 4A,B and see Supplementary Fig. S2). 
Vimentin is a component of the intermediate filament system and a prominent marker of microglia and reactive 
astrocytes23. Up-regulation of vimentin demonstrates that microglia and reactive astrocytes are activated and/or 
are proliferating in response to the presence of injured neural tissues (Fig. 4A,B and see Supplementary Fig. S2). 
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Microglia and astrocytes activation and proliferation were further confirmed by the increased presence of GFAP+ 
cells by immunohistochemistry (Fig. 4C,D). Unlike vimentin expresson, the expression level of CNP was dramat-
ically decreased in the stroke peri-infarct tissue in comparison to that in the contralateral normal tissue (Fig. 4A,B 
and see Supplementary Fig. S2). CNP is a highly expressed enzyme in the myelin sheath and is believed to play 
an essential role in axon myelination24 (Fig. 4A,B and see Supplementary Fig. S2). The decreased CNP expression 
implies neuronal damage and demyelination in stroke24,26. TBN treatment caused a reversal in the expression of 
CNP (Fig. 4A,B and see Supplementary Fig. S2), suggesting possible neuronal repair or regeneration by TBN. In 
accordance with this finding, TBN treatment notably increased the number of NeuN+ neurons with respect to 
the stroke model group (Fig. 4D,E).
Figure 1. TBN attenuates brain infarct volume and improves neurological function in monkeys subjected 
to t-MCAo. (A) Representative images of T2-weighted MRI scan. (B,C) Brain infarct size of ipsilateral 
hemisphere. Data were expressed as dot plots with means in the left panel and mean ± s.e.m. in the right panel 
(n = 6 for each group). (D) Success rate of food catching of the contralateral, stroke-affected hand. Data were 
expressed as mean ± s.e.m. (n = 6 for each group). ‘@3 h’ and ‘@6 h’ mean TBN treatment initiating at 3 h and 6 h 
post-ischemia.
www.nature.com/scientificreports/
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Discussion
The high-order brain of NHP is anatomically and functionally similar to that of humans and is amenable to quan-
titative assessment of the ischemic damage via MRI17. In addition, comprehensive functional evaluations using 
standardized tests are available due to the monkey’s extensive behavioral repertoire17. Researchers hope that mon-
key data will advance the field of stroke therapy with neuroprotective agents. NA-1(also termed Tat-NR2B9c), a 
20-mer peptide functioned as a PSD-95 inhibitor, has been assessed in stroke model macaques monkey and now 
advances into Phase 3 clinical trial2. In reporting NA-1, Cook and his colleagues found that monkeys treated 
with NA-1 exhibited a significant reduction in infarct volume compared with placebo (38.7% reduction by 
T2-weighted MRI scans at 30-day post-stroke), NA-1 was effective even when administrated up to 3 h after the 
onset of stroke2. In our present study, TBN effectively reduced brain infarction by 43.84–56.08% reduction meas-
ured by T2-weighted MRI scans at 28-day post-stroke. More importantly, TBN was still effective administrated 
up to 6 h after the onset of stroke, suggesting that more patients can be treated. In addition to significantly reduced 
brain infarction, TBN treatment also trended to recover the food-catching function of stroke-affected arm. Severe 
1 week 4 weeks
Total 
neurological 
deficit 
(0–77)
Consciousness 
(0–29)
Sensory 
system 
(0–12)
Motor 
system 
(0–17)
Skeletal 
muscle 
coordination 
(0-19)
Successful 
times of right 
hand catching 
(0–15)
Total times 
of right hand 
catching 
(0–15)
Total 
neurological 
deficit (0–77)
Consciousness 
(0–29)
Sensory 
system 
(0–12)
Motor 
system 
(0–17)
Skeletal 
muscle 
coordination 
(0-19)
Successful 
times of right 
hand catching 
(0–15)
Total times 
of right hand 
catching 
(0–15)
Model 21.7 ± 4.1 5.7 ± 0.8 2.0 ± 0.6 7.0 ± 1.7 7.0 ± 1.3 1.0 ± 1.0 3.5 ± 1.0 15.5 ± 1.7 4.3 ± 0.3 2.0 ± 1.0 4.3 ± 0.3 5.0 ± 0.4 1.8 ± 1.6 4.5 ± 0.8
10 mg kg−1 @3 h 20.7 ± 5.6 5.0 ± 0.7 3.3 ± 1.8 6.0 ± 2.0 6.3 ± 1.5 7.5 ± 2.6 8.0 ± 2.4 11.5 ± 2.3 2.7 ± 0.8* 1.5 ± 1.0 3.0 ± 0.7 4.0 ± 0 7.5 ± 3.4* 10.0 ± 2.5*
30 mg kg−1 @3 h 18.7 ± 3.4 5.3 ± 0.7 2 ± 0.6 5.7 ± 1.7 5.7 ± 1.0 8.8 ± 2.6* 10.7 ± 2.6* 14.0 ± 1.6 4.3 ± 0.3 1.0 ± 0.6 4.0 ± 0.5 4.7 ± 0.4 7.7 ± 2.4* 9.0 ± 2.4*
90 mg kg−1 @3 h 19.3 ± 2.6 5.3 ± 0.7 3 ± 0.8 5.0 ± 1.0 6.0 ± 0.9 3.3 ± 1.8 7.8 ± 3.2 11.3 ± 2.8 3.0 ± 1.0 0.5 ± 0.5 3.5 ± 1.0 4.3 ± 1.0 6.2 ± 2.9 7.0 ± 3.0
90 mg kg−1 @6 h 17.3 ± 1.5 5.0 ± 0.4 2.5 ± 0.5 5.0 ± 0.6 5.3 ± 0.4 6.3  ±  2.3 11.7 ± 2.3* 14.0 ± 0.6 4.0 ± 0 2 ± 0.6 4.0 ± 0 4.0 ± 0 9.8 ± 2.4* 11.5 ± 1.9*
Table 1.  Neurological deficit scores of stroke monkeys at 1 and 4 weeks post-surgery. *P < 0.05 versus 
Model. Data at 1 and 4 weeks were separately analyzed by one-way ANOVA, followed by Tukey’s post hoc test. 
‘@3 h’ and ‘@6 h’ meant TBN treatment initiating at 3 h and 6 h post-ischemia.
Figure 2. TBN readily penetrates the blood-brain barrier and reaches neuroprotective concentrations. 
(A,B) Blood and brain cerebrospinal fluid (CSF) concentrations vs. time profile after drug administration. 
(C) TBN protects primary cortical neurons against glutamate-induced excitotoxicity. #P < 0.05 versus control 
(Ctrl); **P < 0.01 versus glutamate treatment alone. Data were from three independent experiments. (D) TBN 
attenuates OGD-induced LDH release in primary cortical neurons. #P < 0.05 versus control (Ctrl); *P < 0.05 and 
**P < 0.01 versus OGD alone. Data were from three independent experiments.
www.nature.com/scientificreports/
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contralateral hemiparesis is a long-lasting and typical clinical presentation after ischemic stroke, with functional 
recovery of the hemiplegic limb considered as a hallmark indicator for evaluation of the efficacy and prognosis 
of stroke therapeutics27. Our result suggests that TBN possibly improves the major clinical manifestations of the 
stroke subjects.
One of the principle features of an effective stroke neuroprotective agent is its ability to penetrate the BBB 
to reach the site of action. NXY-059 has two negatively charged sodium sulfonate moieties, and it is well known 
that negatively charged compounds hardly penetrating BBB6,8. To effectively deliver the free radical-scavenging 
nitrone moiety into brain tissues, TBN was designed using TMP as a carrier. TMP’s superior ability to enter the 
brain was implied as early as 500 years ago in the Compendium of Materia Medica (Bencao Gangmu). Using a 
microdialysis method, Tsai et al. demonstrated that TMP effectively penetrated the BBB, yielding a progressively 
higher brain/blood ratio from 10 to 120 min following intravenous administration28. In our present study, phar-
macokinetic analysis in monkeys demonstrated that TBN readily penetrated the BBB and reached therapeutic 
concentrations in targeted cerebral tissues. This feature of TBN is pivotally important accounting for its high 
therapeutic efficacy.
In addition to taking advantage of TMP’s superior capability to penetrating BBB to deliver the nitrone into 
brain, we also take TMP’s another property, namely its ability to inhibit Ca2+ influx into cells. Thus, TBN can 
effectively enter the injured brain tissues to both inhibit Ca2+ influx and scavenge free radicals, two major causes 
of ischemic neuronal damage29. Previously, we have demonstrated that a multi-functional mechanism, including 
direct scavenging free radicals, blockade of intracellular Ca2+ entry, as well as inhibition of platelet aggregation, 
possibly contributed to TBN’s neuroprotective effects in cellular and in rodent stroke models16.
Tetramethylpyrazine (TMP) has been widely used as a treatment of ischemic stroke for a long time in China. 
A Chinese meta-analysis evaluated the safety of TMP injection plus conventional medicine for acute cerebral 
ischemic stroke. Compared to conventional medicine treatment alone, TMP injection (80–300 mg daily for 14 or 
21 days) plus conventional medicine showed no significant side effects30. In the preclinical study, we compared 
the acute toxicity of TBN (LD50: 858 mg/kg in mice by i.v.) and TMP (LD50: 351 mg/kg in mice by i.v.), TBN was 
two times less toxic than TMP. In addition, because TMP has activities of inhibiting platelet aggregation and 
lysing blood clots, we concern if TBN causes hemorrhage when the drug will presumably be used in conjunction 
with thrombolytic, such as tPA, and anti-platelet agent, such as aspirin. In the preclinical study, we evaluated the 
Figure 3. Dysregulated proteins in quantitative proteomic analyses functionally annotate to cellular 
processes associated with the chronic phase of stroke. (A) Hierarchical cluster analysis of dysregulated 
proteins for the stroke peri-infarct tissue versus the contralateral normal tissue and the TBN-treated peri-
infarct tissue versus the contralateral normal tissue. (B) Dysregulated proteins functionally annotate to cellular 
processes of angiogenesis, neurogenesis, astrogenesis and inflammation.
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effect of TBN on anti-platelet aggregation, and demonstrated that TBN had marginal effect on platelet aggrega-
tion and there was no synergism with aspirin (data not shown). Based on the safety of TMP in clinical use and 
the preclinical safety evaluation of TBN, we speculate that TBN would be safe and has few side effects in human.
Here we used iTRAQ-based quantitative proteomic analyses to elucidate the molecular events involved in 
the long-term benefit effect of TBN. The major cellular processes observed in our proteomic changes were asso-
ciated with the chronic phase of stroke, including angiogenesis, neurogenesis, astrocytosis and inflammation, 
revealing that TBN possibly regulates the brain tissue repair and recovery from stroke injury. In addition, several 
proteins related to various aspects of cellular energy metabolism and mitochondria were downregulated after 
TBN treatment. This suggests that one of the mechanisms involved in neuroprotection of TBN may be similar to 
one involved in hypothermia and ischemic preconditioning, which have been shown to exhibit remarkable neu-
roprotection in laboratory studies and correlated with the downregulation of tissue and cellular metabolism31,32.
CNP is a highly expressed enzyme in the myelin sheath and is believed to play an essential role in axon mye-
lination24, which is essential for the proper function of nervous system33. The decreased CNP expression implies 
neuronal damage and demyelination in stroke24,26. Demyelination, loss of myelin sheath around an axon, causes 
impaired sensation, movement, cognition, or other function aspects depending on which nerves are involved34. 
Remyelination in the peri-infarct area has been observed in the central nerve system after focal ischemia35. In 
both proteomic analysis and Western blotting validation, TBN significantly upregulated the decreased CNP 
expression level in the stroke peri-infarct tissue. Thus, TBN may promote the axon remyelination.
Neurogenesis is an important step in neural development, which plays a vital role in neuronal repair after 
damage during disease processes36–38. After stroke injury, the brain attempts to repair neural cell damage through 
initiation of neurogenesis. It has been reported that TMP could promote the proliferation and differentiation 
of neuronal precursor cells39,40, enhance migration toward the ischemic region in the MCAo rat model41. Adult 
brain has the capacity for self-repair after stroke insults via neuronal replacement from endogenous precursors42 
or a latent neurogenic program in the striatal astrocytes43. Our recent unpublished data suggest that TBN notably 
promotes polarization of cortical neurons in vitro, and increases the production of newly born (BrdU-positive) 
neurons in the peri-infarct area of rat MCAo models.
In the present study, all animal experiments were randomized and blinded by an independent researcher. 
Researchers remained blinded throughout behavioural, imaging, histological assessments. Groups were decoded 
at the end of each experiment upon statistical analysis. The design of this study imitated the clinical rand-
omized and blinded trials to test the preclinical drug efficacy, which reduces the confounding effects of bias. Our 
approach may help to advance the translational roadblock, in which promising preclinical candidates fail to be 
translated to clinically effective treatments44,45. Recently, the clinical trial of TBN for ischemic stroke therapy has 
been approved by the China Food and Drug Administration.
Figure 4. Molecular and cellular events involved in the protection of TBN against stroke injury.  
(A) Representative immunoblots of monkey brain tissue. (B) Densitometric quantification of the immunoblots 
as shown in Supplementary Fig. S1. #P < 0.05 verses contralateral (Cont); *P < 0.05 and **P < 0.01 verses 
ipsilateral (Ipsi) without TBN treatment. (C) Representative immunohistochemistry images of cortical sections. 
Scale bars, 50 μ m. (D) Quantification of the number of NeuN and GFAP positive cells. Data were expressed as 
percentage of sham group (n = 5 for Contralateral; n = 4 Ipsilateral without TBN and n = 6 for Ipsilateral with 
TBN). ##P < 0.01 verses sham group; *P < 0.05 and **P < 0.01 verses model group.
www.nature.com/scientificreports/
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In conclusion, TBN reduced cerebral infarction and improved neurological functions with unique multifunc-
tional mechanisms of action in an ischemic stroke model of non-human primates. Finally, the therapeutic efficacy 
of neuroprotective TBN for ischemic stroke in preclinical findings should be further tested in clinical trials.
Methods
Monkey transient middle cerebral artery (MCA) occlusion (t-MCAo) model. Thirty adult male 
Cynomolgus macaques were used. Animals were 4–5 years of age and 3.0–4.0 kg of body weight at the start of 
the experiment. The animals were housed individually in stainless steel cages with 63 cm wide by 76 cm high 
by 76 cm deep (confirmation to NIH requirement) and maintained on a 12 h light-dark cycle (light on 8:00 to 
20:00), had good visual and auditory interaction with other monkeys. All animals received water ad libitum and 
were provided monkey chow, supplemented with milk, fruit and seeds throughout the day. Primate-specific toys 
and audiovisual media were provided during light hours. Animals were fasted for 12 h before administration of 
anesthesia or behavioral testing.
The details of stroke surgical procedure were described in Supplementary Method. Two monkeys with fail-
ure of ischemic and/or reperfusion were excluded from further experiments. Three monkeys died within 3 h 
post-surgery and before saline or drug administration as a result of surgical/anesthetic complications. No animals 
died because of ischemic stroke or drug treatment during the experimental period, and no animals were excluded 
from data analysis at the end of the experiment.
Body weights were monitored and not significantly affected by surgery and drug treatment during the exper-
imental period (see Supplementary Fig. S3B). The monkeys’ behaviour was measured for 28 days. Brain infarct 
size was inspected using magnetic resonance imaging (MRI) on days 7 and 28 after surgery. The representative 
images of Tof-3D-multi-slab scan at 7 days post stroke showed that the M1 segment of the left middle cerebral 
artery in all monkeys were open (see Supplementary Fig. S4), suggesting that surgical process of MCA reperfu-
sion succeeded, no artery injury and reperfusion good.
Surgery, behavioural testing, MRI inspection and histological analysis were all done blinded to those who 
performed the experiments.
All procedures were performed in accordance with testing facility Standards of Practice (SOP) and regulations 
of Kunming Biomedical International (KBI Ltd., Yunnan Province, China). Animal experimental protocols were 
approved by the institutional animal care and use committee (IACUC) of KBI Ltd., which ensured humane and 
proper care of research animals. All efforts were made to minimize the numbers of animals used and ensure 
minimal suffering.
Experimental groups. Thirty monkeys with successful t-MCAo surgery were block-randomly divided into 
five groups with 6 per group: (1) Model, stroke animals treated with saline; (2) 10 mg kg−1 TBN; (3) 30 mg kg−1; 
(4) 90 mg kg−1 TBN; (5) 90 mg kg−1 TBN delayed treatment. On the day of surgery, saline or drugs (dissolved in 
saline) were given (i.v. bolus, 1 mL kg−1) at 3 and 6 h (groups 1–4) or at 6 and 9 h (group 5) after t-MCAo. Drugs 
were then given twice daily for a total of 7 days post-surgery. TBN (Lot. No. 20101102, purity 99.3%) used in this 
study was synthesized by Shanghai Medicilon Inc. (Shanghai, China).
Assessment of neurological behavior. The neurological severity score (NSS), based on that described 
by Kito et al.46, included assessments of consciousness, sensory and motor system function, and skeletal muscle 
coordination (see Supplementary Table 3). In addition to the NSS, we also tested the functional recovery of the 
contralateral limb using food catching. The monkeys were measured on their ability to freely catch food (apple 
pieces of 1 cm3 cubic shape). Before the stroke surgery, all monkeys were trained to successfully catch 15 pieces 
of apple within 5 min using their both limbs. When food catching task was performed, monkey was restrained 
in a special monkey chair (as shown in Supplementary Movie 1 and 2), their left limbs could only reach the left 
foot container, and their right limbs could only reach the right foot container. Then, the numbers of successful 
catching and total catching (times of touching the food container, including successful and failed catching) using 
both limbs were recorded. The success rate of food catching was calculated as: times of successful catching/times 
of total catching× 100%.
Evaluation of brain infarct size by MRI. For the imaging study, after the animals had been anesthe-
tized by intramuscular administration of ketamine hydrochloride (10 mg kg−1) containing atropine sulfate 
(0.05 mg kg−1), MRI imaging was performed from the frontal to the posterior brain regions employing an MRI 
scanner (Siemens-MR-Verio 3.0, Siemens, Germany) with Tof-3D-multi-slab, T1-f12d-tra and T2-tse-tra scan. 
The sequence of Tof-3D-multi-slab was the cerebrovascular dynamic scanning for determining cerebral blood 
vessel integrity and patency. The sequence of T1-f12d-tra scan determined the gross anatomy map of animal brain 
tissue. The sequence of T2-tse-tra scan detected the infarct area of animal brain tissue, in which the infarct area 
showed high signal and normal brain tissue showed low signal. Transverse images with a 4-mm slice thickness 
were obtained from each T2-MRI sequence. The infarct size on T2-MRI imaging of the ischemic side was defined 
as the white portions and was compared to those on the contralateral side using Adobe Photoshop 7.0 software 
(San Jose, CA, USA).
Tissue preparation. At termination of the experiment, monkeys were euthanized with a sodium pentobar-
bital overdose (150 mg kg−1, i.v.). The brain was removed and 4 mm brain slices (total 12 pieces from each brain) 
were sectioned coronally on ice with the brain immersed in cold saline (0.9%) for less than 15 min. For every 
brain slice within the areas of visible infarct, the normal cerebral cortex of the contralateral cerebral hemisphere 
and the peri-infarct area (adjacent to infarcted tissue) of the cerebral cortex from the ipsilateral hemisphere 
were dissociated for protein extraction and proteomics analysis. The tissues were immediately frozen in liquid 
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nitrogen, and stored at − 80 °C. The other brain slices were immersed in 4% paraformaldehyde to fix for 48 h. The 
tissues were then processed for histopathologic evaluation.
Pharmacokinetics. Six Cynomolgus macaque monkeys were used for pharmacokinetic study. TBN were 
given intravenously at doses of 30 and 90 mg kg−1, 3 monkeys for each dose. Blood samples were collected 
through the hind limb vein using 5 mL heparinized syringes at 0, 2.5, 5, 10, 20, 40, 80 and 160 min post drug 
administration. Blood samples were centrifuged at 3,200 g for 10 min at 4 °C. Following centrifugation, plasma 
was collected and frozen until further analysis.
After the animals were anesthetized by intramuscular administration of ketamine hydrochloride (10 mg kg−1) 
containing atropine sulfate (0.05 mg kg−1), cerebrospinal fluid samples were collected from the cisterna magna at 
15, 45, 60 and 120 min post drug administration. Drug concentrations were determined by HPLC analysis.
Primary cortical neurons culture and neuroprotective assays. We prepared cortical cultures from 
E18 rat embryos (Experimental Animal Center of Sun Yat-Sen University) as previously described47. Cortical 
neurons were grown at 37 °C in a humidified incubator with 5% CO2/95% air atmosphere. After 4–6 h, unattached 
cells and debris were removed by replacing the initial medium with fresh neurobasal medium containing B27 sup-
plements. Subsequent partial medium replacement was carried out twice a week and cultures at 11 days were used 
for the experiments. TBN at indicated concentrations were applied 2 h before exposure to glutamate (200 μ M), 
and the cells were cultured for another 24 h. Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) assay15.
The neuroprotective effect of TBN was further assessed by attenuation of LDH release on OGD-insulted corti-
cal neurons. TBN at indicated concentrations were applied 2 h before exposure to OGD for 4 h, and the cells were 
cultured for another 24 h. LDH release assay was conducted according to our previous report48.
Isobaric tags for relative and absolute quantitation (iTRAQ)-based quantitative proteomic anal-
yses. The details of iTRAQ-based quantitative proteomic analyses were described in Supplementary Methods, 
including proteomics sample preparation, iTRAQ labelling, liquid chromatography, mass spectrometry and data 
analysis, and iTRAQ ratio calculations and criteria for the selection of dysregulated proteins.
Western blotting. For protein extraction, tissues were extracted with RIPA lysis buffer containing 1% PMSF 
and 1% protease inhibitor cocktail on ice for 10 min. The lysates were centrifuged (12,500 × g, 20 min, 4 °C) and 
the supernatants were then collected and stored at –80 °C until use. Protein contents were assayed using a BCA 
protein quantification kit (Pierce, Rockford, IL, USA). Protein samples (30 μ g) were resolved using SDS-PAGE 
and transferred to PVDF membranes. The immunoblots were analyzed with the appropriate primary antibodies 
(1:1000). Horseradish peroxidase-conjugated secondary antibodies (1:2500) were used to detect the proteins of 
interest through enhanced chemiluminescence.
Immunohistochemistry. The fixed brain slices were dehydrated with graded alcohol, embedded in par-
affin wax, and coronally sectioned at 6 μ M. Immunohistochemistry of sections was performed using antibodies 
against glial fibrillary acidic protein (GFAP, Cat.no. MAB360, Millipore) and neuronal nuclei (NeuN, Cat.no. 
MAB 377, Millipore) to evaluate the infiltration of inflammatory cells and viability of neurons. The positive cells 
were randomly counted in 5 areas per section and 3 sections of each monkey from 6 monkeys per group, and then 
averaged the data.
Data and statistical analyses. We carried out statistical analysis with Prism 6.0 software (GraphPad 
Software). Unless otherwise specified, all data were expressed as mean ± s.e.m, and multiple comparisons were 
assessed by one-way ANOVA followed by the Tukey’s post hoc test for significance. The significance level was set 
as P < 0.05.
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